The MRC Centre for Protein Engineering (or CPE) was a pioneering research unit in Cambridge, England, with a main focus on the structure, stability and activity of proteins and engineering of antibodies. From 1990 to 2010 the unit has been extremely successful, both academically and commercially. All of Sir Alan's work on protein folding and much of Sir Greg's pioneering work to humanise antibodies was carried out at CPE. For example, Cambridge Antibody Technology was a biotechnology company founded by Sir Greg Winter in 1989 that was bought for £702 million in 2006 by AstraZeneca.